Clinical Trials Browser

Prostatic Neoplasms × LFA102 monoclonal antibody × Clear all

NCT01338831 2020-12-17

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms, Myofibroma